Anaritide (Auriculin-Registered Trademark) is a 25-amino-acid synthetic form of atrial natriuretic peptide. Scios Nova was developing anaritide acetate for use in the treatment, prevention and diagnosis of acute renal failure, heart failure and hypertension. Scios suspended development of AURICULIN® anaritide based upon the results of an interim analysis of data from a 250-patient Phase III study in oliguric acute renal failure. The study was suspended due to the low probability that a positive outcome could be obtained with respect to its primary clinical endpoint, dialysis-free survival.
Originator
Approval Year
Sample Use Guides
Acute tubular necrosis: The patients received a 24-hour intravenous infusion of either anaritide (0.2 microgram per kilogram of body weight per minute)
Route of Administration:
Intravenous
In in vitro perfused hydronephrotic rat kidney model Anaritide completely reversed the NE-induced AA vasoconstriction with an IC50 of 9.3 +/- 5.6 nM. In contrast, ANP caused a further decrease in EA diameter at concentrations up to 10(-8) M, and elicited a slight dilation of the EA at 10(-7) M.
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 01:12:16 GMT 2023
by
admin
on
Sat Dec 16 01:12:16 GMT 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
EGV6V52K6N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
62291
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
||
|
NCI_THESAURUS |
C548
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
62391
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Y-37
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
PRIMARY | |||
|
EGV6V52K6N
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
PRIMARY | |||
|
104595-79-1
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108934
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
PRIMARY | |||
|
118984442
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
PRIMARY | |||
|
C77222
Created by
admin on Sat Dec 16 01:12:16 GMT 2023 , Edited by admin on Sat Dec 16 01:12:16 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
STARTING MATERIAL -> INGREDIENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|